Selective acquired long QT syndrome (saLQTS) upon risperidone treatment

BMC Psychiatry

Panteleimon Giannakopoulos²  Nicolas Perrin¹  Zahir A Bhuiyan³  Maciej Jakub Lazarczyk¹ 

[1] Division of General Psychiatry, University Hospitals of Geneva and Faculty of Medicine of the University of Geneva, 1202 Geneva, Switzerland;Division of Old Age Psychiatry, Hospices-CHUV, 1008, Prilly, Switzerland;Laboratoire de Génétique Moléculaire, Service de Génétique Médicale, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland

关键词: hERG;    KCNH2;    Clozapine;    Risperidone;    Antipsychotic;    QT;    Selective acquired long QT syndrome;    Acquired long QT syndrome;    Long QT syndrome;   

Others  :  1124212
DOI  :  10.1186/1471-244X-12-220

 received in 2012-06-28, accepted in 2012-11-23,  发布年份 2012

【 摘 要 】

Background

Numerous structurally unrelated drugs, including antipsychotics, can prolong QT interval and trigger the acquired long QT syndrome (aLQTS). All of them are thought to act at the level of KCNH2, a subunit of the potassium channel. Although the QT-prolonging drugs are proscribed in the subjects with aLQTS, the individual response to diverse QT-prolonging drugs may vary substantially.

Case presentation

We report here a case of aLQTS in response to small doses of risperidone that was confirmed at three independent drug challenges in the absence of other QT-prolonging drugs. On the other hand, the patient did not respond with QT prolongation to some other antipsychotics. In particular, the administration of clozapine, known to be associated with higher QT-prolongation risk than risperidone, had no effect on QT-length. A detailed genetic analysis revealed no mutations or polymorphisms in KCNH2, KCNE1, KCNE2, SCN5A and KCNQ1 genes.

Conclusions

Our observation suggests that some patients may display a selective aLQTS to a single antipsychotic, without a potassium channel-related genetic substrate. Contrasting with the idea of a common target of the aLQTS-triggerring drugs, our data suggests existence of an alternative target protein, which unlike the KCNH2 would be drug-selective.

【 授权许可】

   
2012 Lazarczyk et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT: A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995, 80:795-803.
• [2]Kannankeril P, Roden DM, Darbar D: Drug-induced long QT syndrome. Pharmacol Rev 2010, 62:760-781.
• [3]Viskin S, Justo D, Halkin A, Zeltser D: Long QT syndrome caused by noncardiac drugs. Prog Cardiovasc Dis 2003, 45:415-427.
• [4]Stöllberger C, Huber JO, Finsterer J: Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005, 20:243-251.
• [5]Roden DM, Viswanathan PC: Genetics of acquired long QT syndrome. J Clin Invest 2005, 115:2025-2032.
• [6]Saenen JB, Vrints CJ: Molecular aspects of the congenital and acquired Long QT Syndrome: clinical implications. Mol Cell Cardiol 2008, 44:633-646.
• [7]Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W, Breithardt G, Cohen N, Aerssens J: Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients. J Mol Med (Berl) 2004, 82:182-188.
• [8]Suzuki Y, Fukui N, Watanabe J, Ono S, Sugai T, Tsuneyama N, Saito M, Inoue Y, Someya T: QT prolongation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite paliperidone. Hum Psychopharmacol 2012, 27:39-42.
• [9]Yang FD, Wang XQ, Liu XP, Zhao KX, Fu WH, Hao XR, Zhang XL, Huang GS, Qu SC, Bai JS, Huang XF, Kosten TR, Zhang XY: Sex difference in QTc prolongation in chronic institutionalized patients with schizophrenia on long-term treatment with typical and atypical antipsychotics. Psychopharmacology (Berl) 2011, 216:9-16.
• [10]Nishio Y, Makiyama T, Itoh H, et al.: D85N, a KCNE1 polymorphism, is a disease-causing gene variant in long QT syndrome. J Am Coll Cardiol 2009, 54:812-819.
• [11]Gouas L, Nicaud V, Chaouch S, Berthet M, Forhan A, Tichet J, Tiret L, Balkau B, Guicheney P: Confirmation of associations between ion channel gene SNPs and QTc interval duration in healthy subjects. Eur J Hum Genet 2007, 15:974-979.
• [12]Tristani-Firouzi , Sanguinetti MC: Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. J Mol Cell Cardiol 2003, 35:27-35.
• [13]Hayashi K, Shuai W, Sakamoto Y, Higashida H, Yamagishi M, Kupershmidt S: Trafficking-competent KCNQ1 variably influences the function of HERG long QT alleles. Heart Rhythm 2010, 7:973-980.
• [14]Harrigan EP, Miceli JJ, Anziano R, Watsky E, Reeves KR, Cutler NR, Sramek J, Shiovitz T, Middle M: A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004, 24:62-69.
• [15]Hedley PL, Jørgensen P, Schlamowitz S, Wangari R, Moolman-Smook J, Brink PA, Kanters JK, Corfield VA, Christiansen M: The genetic basis of long QT and short QT syndromes: a mutation update. Hum Mutat 2009, 30:1486-1511.